Results 91 to 100 of about 29,990 (207)
The Concise Guide to PHARMACOLOGY 2025/26: G protein‐coupled receptors
British Journal of Pharmacology, Volume 182, Issue S1, Page S24-S151, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +206 more
wiley +1 more source
Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease. [PDF]
, 2011 BACKGROUND: Cyst infection remains a challenging issue in patients with autosomal dominant polycystic kidney disease (ADPKD). In most patients, conventional imaging techniques are inconclusive.
Beguin, Claire +6 more
core +1 more source
The FEBS Journal, Volume 292, Issue 23, Page 6182-6194, December 2025.Enzymes from the phosphodiesterase type 4 family (PDE4) coordinate physiological events driven by the cyclic AMP s(cAMP) signaling pathway by tightly controlling cAMP dynamics in many cell types. Key to this strict regulation is the myriad of posttranslational modifications that alter PDE4 activity, cellular location, and binding partner selection ...
Madihah Hussain +2 more
wiley +1 more source
p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. [PDF]
, 2007 BackgroundAutosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease with few treatment options other than renal replacement therapy. p21, a cyclin kinase inhibitor which has pleiotropic effects on the cell cycle, in many cases acts
Anderson, Sharon +6 more
core +3 more sources
Autosomal dominant polycystic kidney disease: updated perspectives
Therapeutics and Clinical Risk Management, 2019 Anjay Rastogi,1 Khalid Mohammed Ameen,1 Maha Al-Baghdadi,1 Kelly Shaffer,1 Niloofar Nobakht,1 Mohammad Kamgar,1 Edgar V Lerma21Department of Medicine, Division of Nephrology, David Geffen School of Medicine, Los Angeles, CA, USA; 2Department of Medicine,
Rastogi A +6 more
doaj
Aldosterone as a renal growth factor [PDF]
, 2010 Aldosterone regulates blood pressure through its effects on the cardiovascular system and kidney. Aldosterone can also contribute to the development of hypertension that leads to chronic pathologies such as nephropathy and renal fibrosis.
Dooley, Ruth +2 more
core +1 more source
Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease [PDF]
European Medical Journal Nephrology, 2015 Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 people in the general population. The natural history of ADPKD includes the progression of chronic kidney disease to end-stage renal disease (ESRD) in a large ...
Andrzej Kulesza +2 more
doaj
Expression of Nek1 during kidney development and cyst formation in multiple nephron segments in the Nek1-deficient kat2J mouse model of polycystic kidney disease [PDF]
, 2014 BACKGROUND: Neks, mammalian orthologs of the fungal protein kinase never-in-mitosis A, have been implicated in the pathogenesis of polycystic kidney disease. Among them, Nek1 is the primary protein inactivated in kat2J mouse models of PKD.
Charity Juang +5 more
core +3 more sources
Activation of PIEZO1 Attenuates Kidney Cystogenesis In Vitro and Ex Vivo
Kidney360Key Points. PIEZO1 activation reduces cystogenesis: Yoda1 activates PIEZO1, raising calcium and lowering cAMP, reducing cyst growth in autosomal dominant polycystic kidney disease models.
Qingfeng Fan +12 more
doaj +1 more source
Molecular Genetics & Genomic Medicine, 2020 Background Polycystic kidney disease (PKD) is an inherited disease that is life‐threatening. Multiple cysts are present in the bilateral kidneys of PKD patients.
Kexian Dong +16 more
doaj +1 more source